Literature DB >> 9502772

Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome.

A Lomri1, J Lemonnier, M Hott, N de Parseval, E Lajeunie, A Munnich, D Renier, P J Marie.   

Abstract

Apert syndrome, associated with fibroblast growth factor receptor (FGFR) 2 mutations, is characterized by premature fusion of cranial sutures. We analyzed proliferation and differentiation of calvaria cells derived from Apert infants and fetuses with FGFR-2 mutations. Histological analysis revealed premature ossification, increased extent of subperiosteal bone formation, and alkaline phosphatase- positive preosteoblastic cells in Apert fetal calvaria compared with age-matched controls. Preosteoblastic calvaria cells isolated from Apert infants and fetuses showed normal cell growth in basal conditions or in response to exogenous FGF-2. In contrast, the number of alkaline phosphatase- positive calvaria cells was fourfold higher than normal in mutant fetal calvaria cells with the most frequent Apert FGFR-2 mutation (Ser252Trp), suggesting increased maturation rate of cells in the osteoblastic lineage. Biochemical and Northern blot analyses also showed that the expression of alkaline phosphatase and type 1 collagen were 2-10-fold greater than normal in mutant fetal calvaria cells. The in vitro production of mineralized matrix formed by immortalized mutant fetal calvaria cells cultured in aggregates was also increased markedly compared with control immortalized fetal calvaria cells. The results show that Apert FGFR-2 mutations lead to an increase in the number of precursor cells that enter the osteogenic pathway, leading ultimately to increased subperiosteal bone matrix formation and premature calvaria ossification during fetal development, which establishes a connection between the altered genotype and cellular phenotype in Apert syndromic craniosynostosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9502772      PMCID: PMC508685     

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

Review 1.  Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction.

Authors:  M Jaye; J Schlessinger; C A Dionne
Journal:  Biochim Biophys Acta       Date:  1992-06-10

2.  In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats.

Authors:  H Mayahara; T Ito; H Nagai; H Miyajima; R Tsukuda; S Taketomi; J Mizoguchi; K Kato
Journal:  Growth Factors       Date:  1993       Impact factor: 2.511

Review 3.  Structural and functional diversity in the FGF receptor multigene family.

Authors:  D E Johnson; L T Williams
Journal:  Adv Cancer Res       Date:  1993       Impact factor: 6.242

4.  Kinetics of in vitro mineralization by an osteogenic clonal cell line (C1) derived from mouse teratocarcinoma.

Authors:  J Chentoufi; M Hott; D Lamblin; M H Buc-Caron; P J Marie; O Kellermann
Journal:  Differentiation       Date:  1993-07       Impact factor: 3.880

5.  Effect of basic fibroblast growth factor on the growth and differentiation of adult stromal bone marrow cells: enhanced development of mineralized bone-like tissue in culture.

Authors:  S Pitaru; S Kotev-Emeth; D Noff; S Kaffuler; N Savion
Journal:  J Bone Miner Res       Date:  1993-08       Impact factor: 6.741

6.  Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3.

Authors:  D M Ornitz; P Leder
Journal:  J Biol Chem       Date:  1992-08-15       Impact factor: 5.157

7.  Decreased DNA synthesis by cultured osteoblastic cells in eugonadal osteoporotic men with defective bone formation.

Authors:  P J Marie; M C de Vernejoul; D Connes; M Hott
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

8.  Basic fibroblast growth factor inhibits type I collagen gene expression in osteoblastic MC3T3-E1 cells.

Authors:  M M Hurley; C Abreu; J R Harrison; A C Lichtler; L G Raisz; B E Kream
Journal:  J Biol Chem       Date:  1993-03-15       Impact factor: 5.157

9.  Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome.

Authors:  W Reardon; R M Winter; P Rutland; L J Pulleyn; B M Jones; S Malcolm
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

10.  Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats.

Authors:  T Nakamura; K Hanada; M Tamura; T Shibanushi; H Nigi; M Tagawa; S Fukumoto; T Matsumoto
Journal:  Endocrinology       Date:  1995-03       Impact factor: 4.736

View more
  37 in total

1.  In vivo modulation of FGF biological activity alters cranial suture fate.

Authors:  J A Greenwald; B J Mehrara; J A Spector; S M Warren; P J Fagenholz; L E Smith; P J Bouletreau; F E Crisera; H Ueno; M T Longaker
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

2.  A TWIST in the fate of human osteoblasts identifies signaling molecules involved in skull development.

Authors:  E W Jabs
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

3.  Concerted action of Msx1 and Msx2 in regulating cranial neural crest cell differentiation during frontal bone development.

Authors:  Jun Han; Mamoru Ishii; Pablo Bringas; Richard L Maas; Robert E Maxson; Yang Chai
Journal:  Mech Dev       Date:  2007-07-10       Impact factor: 1.882

Review 4.  The molecular and cellular basis of Apert syndrome.

Authors:  Chao Liu; Yazhou Cui; Jing Luan; Xiaoyan Zhou; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2013-11

5.  Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation.

Authors:  A Montero; Y Okada; M Tomita; M Ito; H Tsurukami; T Nakamura; T Doetschman; J D Coffin; M M Hurley
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 6.  Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies.

Authors:  Pierre J Marie
Journal:  Cell Mol Life Sci       Date:  2014-12-09       Impact factor: 9.261

7.  Postnatal brain and skull growth in an Apert syndrome mouse model.

Authors:  Cheryl A Hill; Neus Martínez-Abadías; Susan M Motch; Jordan R Austin; Yingli Wang; Ethylin Wang Jabs; Joan T Richtsmeier; Kristina Aldridge
Journal:  Am J Med Genet A       Date:  2013-03-12       Impact factor: 2.802

8.  Activation of the IGF1 pathway mediates changes in cellular contractility and motility in single-suture craniosynostosis.

Authors:  Zeinab Al-Rekabi; Marsha M Wheeler; Andrea Leonard; Adriane M Fura; Ilsa Juhlin; Christopher Frazar; Joshua D Smith; Sarah S Park; Jennifer A Gustafson; Christine M Clarke; Michael L Cunningham; Nathan J Sniadecki
Journal:  J Cell Sci       Date:  2015-12-11       Impact factor: 5.285

9.  Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice.

Authors:  Yingli Wang; Miao Sun; Victoria L Uhlhorn; Xueyan Zhou; Inga Peter; Neus Martinez-Abadias; Cheryl A Hill; Christopher J Percival; Joan T Richtsmeier; David L Huso; Ethylin Wang Jabs
Journal:  BMC Dev Biol       Date:  2010-02-22       Impact factor: 1.978

10.  Scalp fibroblasts have a shared expression profile in monogenic craniosynostosis.

Authors:  Elena G Bochukova; Shamit Soneji; Steven A Wall; Andrew O M Wilkie
Journal:  J Med Genet       Date:  2009-09-15       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.